HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
St. Louis October 16, 2021 Myeloma Round Table
St. Louis October 16, 2021 Myeloma Round Table image
HealthTree Round Tables for Multiple Myeloma Chapter
event Oct 16, 2021 / 09:00AM - 03:30PM CDT

Event Description

If distance, time, or caution about the pandemic is preventing you from attending the St. Louis Myeloma Crowd Round Table featuring six top myeloma experts, you can register here for the live webcast of the meeting on October 16, 2021.

The program, focusing on two topics: Immunotherapy: Clinical Use and Barriers and Personalized Medicine: Ready for Myeloma?, will run from 9:00 am-3:30 pm.

Session one will begin at 9:00 am Central (7 am Pacific, 8 am Mountain, 10 am Eastern, 11 am Atlantic, 15:00 GMT, 16:00 CET) and session two will begin at 1 pm Central (11 am Pacific, 12 pm Mountain, 2 pm Eastern, 3 pm Atlantic, 19:00 GMT, 20:00 CET).

Learn from these top myeloma experts about the latest research and treatment to find out what you can do to stay one step ahead for your best outcomes.  Extensive time for audience questions is included in every Round Table.

Please contact Greg Brozeit at or 330-990-1090 if you have any questions.

Watch the October 16, 2021 Round Table

Immunotherapy (Part 1)


Audience Questions & Answers (Part 1)


Personalized Medicine (Part 2)


Audience Questions & Answers (Part 2)


Schedule & Agenda

Myeloma Crowd Round Table Session One
Myeloma Crowd Round Table Session One
Meeting Logistics
Understanding Concepts of Immunotherapy
* The immune system and cancer * Approach to immunotherapy of cancer * Can immunotherapies affect progression from precursor stages?
Creating an Immunotherapy Treatment Strategy
* Barriers and other considerations * Immunotherapy trials in myeloma * Balancing approved therapies, clinical trials, and expectations
Immunotherapies in the Clinic
* A clinical case study of immunotherapy * Challenges in the clinic * Opportunities and rewards in the clinic
Myeloma Crowd Round Table Session One
HealthTree Cure Hub: Real Word Evidence for You and Researchers
* Demonstration of features to help you understand and manage your disease * How you can help advance research to discover cures
Myeloma Crowd Round Table Session One
Audience Question & Answers
Personalized Medicine: When and How?
* The tool kit of personalized medicine * Learning from experiences of other cancers * Novel trial designs
Bringing Personalized Medicine to Myeloma
* Developing a personalized approach to treating myeloma * Barriers to personalized medicine in myeloma * Personalized medicine trials in myeloma
Myeloma Crowd Round Table Session Two
Personalized Medicine in Myeloma Treatment
* Two case studies * How clinical experience is informing future decision-making * A potential case study: Imaging the promise of personalized medicine
Myeloma Crowd Round Table Session Two
Audience Questions & Answers
Myeloma Crowd Round Table Session Two
Closing Remarks

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio
The panelist Todd Foster
Todd Foster

Todd Foster is the head of Product at HealthTree, he is an IT healthcare executive who specializes in patient experience and clinical process improvements. Todd was director of Patient and Provider Experience at MD Anderson for over a decade. Prior experience includes leadership of IT development projects at Intermountain HealthCare and United HealthCare. Todd has a passion for using technology that can help patients have a better life and along the way, help to further research for a cure.

Read Bio
The panelist Ivan Borrello, MD
Ivan Borrello, MD

Ivan Borrello, MD, is associate professor of oncology at the Johns Hopkins University School of Medicine and director of the Cell Therapy and cGMP Biologics Core for the Johns Hopkins Kimmel Cancer Center. He is a member of the Hematologic Malignancies and Bone Marrow Translational Program. Dr. Borello’s clinical research interest is in developing immune based therapies for the treatment of multiple myeloma. HIs laboratory interests have focused on the development of a novel approach of adoptive T cell therapy utilizing marrow infiltrating lymphocyte (MILs) as a more tumor specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins, and he is currently exploring this approach in other diseases including non-hematologic malignancies. Dr. Borrello is also examining strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines. Dr. Borello served a fellowship at the Johns Hopkins School of Medicine, completed his residency in internal medicine at the University of Chicago Pritzker School of Medicine, and earned his medical degree from the Medical College of Virginia.

Read Bio
The panelist Greg Brozeit
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Read Bio
The panelist Madhav Dhodapkar, MBBS
Madhav Dhodapkar, MBBS

Madhav V. Dhodapkar, MBBS, is the Anise McDaniel Brock Chair and Georgia Research Alliance Eminent Scholar in Cancer Innovation and Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Dhodapkar serves as director of the Winship Center for Cancer Immunology, and as leader of the Cancer Immunology Research Program at Winship Cancer Institute. Prior to joining Emory, he served as Chief of Hematology, the Arthur H. and Isabel Bunker Professor of Medicine (Hematology), and Professor of Immunobiology at Yale University School of Medicine. An expert in the treatment of multiple myeloma, he also was co-director of the Cancer Immunology Program within the Yale Cancer Center. Other faculty appointments include Myeloma Institute in Little Rock, Arkansas, Memorial Sloan Kettering Cancer Center in New York, New York, and The Rockefeller University in New York, New York. A board certified hematologist and medical oncologist, Dr. Dhodapkar specializes in the treatment of multiple myeloma and other hematological malignancies. His primary clinical and scholarly focus is the immuno-biology of myeloma and the development of novel biological approaches to treat cancer. Dr. Dhodapkar received his Medical Degree from the All India Institute of Medical Sciences in New Delhi. He completed his residency in internal medicine at St. Louis University, and his fellowship in hematology and medical oncology at the Mayo Clinic in Rochester, Minnesota.

Read Bio
The panelist Mark Schroeder, MD
Mark Schroeder, MD

Mark Schroeder, MD, is Associate Professor of Medicine, Division of Oncology, Section of Blood and Marrow Transplantation at Washington University School of Medicine. Dr. Schroeder is a graduate of the University of Cincinnati College of Medicine and completed his residency in Internal Medicine and fellowship in Hematology and Oncology at Washington University in St. Louis. He joined faculty at Washington University in 2009. He is a member of the Siteman Cancer Center and serves on the National Comprehensive Cancer Network Hematopoietic Cell Transplant Panel. Dr. Schroeder’s clinical research focuses on multiple myeloma, graft versus host disease, and stem cell transplant biology.

Read Bio
The panelist Shaji Kumar, MD
Shaji Kumar, MD

Shaji Kumar, MD, is a Professor of Medicine and a Consultant in the Division of Hematology at the Mayo Clinic, Rochester, MN. His research focuses on development of novel drugs for treatment of myeloma. His research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Dr. Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes. His work on drug development is complemented by an active program studying the biology of myeloma, with a focus on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma. His clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease. Dr. Kumar conducts National Institutes of Health-funded research on translation of novel therapeutic targets in multiple myeloma as well as the role of cereblon pathways in myeloma. He also receives funding from the Multiple Myeloma Research Foundation to study the relationship between molecular profiles, treatment regimens for patients with multiple myeloma and outcomes. Additional research, funded by the National Cancer Institute, investigates the prevalence, onset and biomarkers for progression of monoclonal gammopathies. Dr. Kumar was a research associate at the Dana-Farber Cancer Institute in the Harvard Cancer Center, a fellow at the Mayo Clinic, and received his medical degree and completed an internship and clinical residencies at the All-India Institute of Medical Sciences.

Read Bio
The panelist Ravi Vij, MD, MBA
Ravi Vij, MD, MBA

Ravi Vij, MD, MBA, is Professor of Medicine at the Washington University School of Medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia. Dr. Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation. He has research interests in multiple myeloma and AML/myelodysplastic syndromes. Dr. Vij serves on numerous committees including the International Myeloma Working Group (IWMG), the Core Transplant Myeloma and Leukemia Committees of the CALGB, the Steering Committee of the Multiple Myeloma Research Consortium, and the Myeloma Committee of the BMT Clinical Trials Network (CTN). His honors include the Multiple Myeloma Research Foundation Innovator Award (2013) and the Multiple Myeloma Research Consortium Center of Excellence Award (2011). He has authored more than 130 publications in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation. He has authored the book Contemporary Management of Multiple Myeloma and several chapters in books, including Multiple Myeloma and Plasma Cell Dyscrasias in the Washington Manual of Oncology. He has served as a review for journals including Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Experimental Hematology and Haematologica.

Read Bio
The panelist Surbhi Sidana, MD
Surbhi Sidana, MD

Dr. Sidana is a hematologist/oncologist trained in advanced hematology with an emphasis on myeloma, amyloidosis, and dysproteinemia disorders. She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine. She leads the Myeloma Cellular Immunotherapy program at Stanford. Her areas of expertise include transplantation and novel cellular immunotherapies such as CAR-T-cell therapy for patients with multiple myeloma. For each patient, Dr. Sidana develops a personalized care plan designed to optimize outcomes and quality of life. Dr. Sidana conducts extensive research. Currently, she is conducting clinical trials of CAR-T therapy and bispecific T-cell engagers for treatment of patients with myeloma. She is studying patients’ access to CAR-T cell therapy, the financial burden of the treatment, and its impact on patients’ quality of life and cognitive function. Dr Sidana has received a grant from the Stanford Medicine Cancer Institute and NIH funding through the Stanford KL2 program to study adverse events of CAR-T therapy on patients and monitoring of patients undergoing CAR-T therapy using wearable devices.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube